Overall, the main mechanisms responsible for the hypolipidemic effects of apigenin include: decreasing dyslipidemia and subsequent atherosclerotic conditions via down-regulating SREBP-1c, SREBP-2, FAS, Stearyl-CoA desaturase 1, HMG-CoA reductase, and expression of TLR-4 which are involved in inflammation and atherosclerotic plaques formation. This evidence concerns the gene SREBF2 and metabolic syndrome.